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Abstract: During the last decade a large number of biological agents against tumor necrosis 
factor-α (TNF-α), as well as many biochemical substances and molecules specifically for the 
medical treatment of patients with inflammatory bowel disease (IBD), have been developed. 
This enormous progress was a consequence of the significant advances in biotechnology along 
with the increased knowledge of the underlying pathophysiological mechanisms involved in 
the pathogenesis of IBD. However, conventional therapies remain the cornerstone of treatment 
for most patients. During recent years conventional and biologic IBD therapies have been 
optimized. Newer mesalazine formulations with a reduced pill size and only one dose per day 
demonstrate similar efficacy to older formulations. New corticosteroids retain the efficacy of 
older corticosteroids while exhibiting a higher safety profile. The role of antibiotics and probiotics 
has been further clarified. Significant progress in understanding thiopurine metabolism has 
improved the effective dose along with adjunctive therapies. Quite a large number of substances 
and therapies, including biologic agents other than TNF-α inhibitors, unfractionated or low-
molecular-weight heparin, omega-3 polyunsaturated fatty acids, microbes and microbial products, 
leukocytapheresis, and other substances under investigation, could offer important benefits to our 
patients. In this paper we review the established and emerging therapeutic strategies in patients 
with Crohn’s disease and ulcerative colitis.
Keywords: inflammatory bowel disease, ulcerative colitis, Crohn’s disease, treatment, biologic 
agents, immunosuppressives, mesalazine, antibiotics
Introduction
Inflammatory bowel disease (IBD) is a chronic, relapsing, inflammatory disorder 
of the gastrointestinal tract that includes two entities, namely Crohn’s disease (CD) 
and ulcerative colitis (UC). In the last decade, our understanding of the etiology and 
pathogenesis of IBD has improved considerably.
Treatment of the disease includes conservative measures as well as surgical 
approaches in those who are non-responders to medical treatment. The primary 
therapeutic goals are related to improvement of patient quality of life by inducing and 
maintaining remission, predicting, preventing and treating complications, restoring 
nutritional deficits, providing appropriate psychosocial support, and modifying the 
course in those with aggressive disease.
Pharmaceutical treatment of IBD includes five major categories, namely anti-
inflammatory drugs, immunosuppressants, biologic agents, antibiotics, and drugs 
for symptomatic relief. Several other pharmaceutical substances have been   produced 
and studied in recent years, the implementation of which was the result of an Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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increased knowledge of the underlying pathophysiological 
mechanisms.
There is now a general consensus that IBD is the result of 
the combined effects of 4 factors: environmental influences, 
genetic variations, intestinal microbiota alterations, and 
disturbances in the innate and adaptive immune responses. 
A combination of all these factors is probably necessary for 
the disease to be clinically expressed. However, it seems that 
each patient has a different combination of factors leading to 
the disease, explaining why each patient displays their own 
clinical picture and response to therapy.1
The intestine is the largest lymphoid organ in the body 
because of the huge antigen load to which it is exposed on 
a daily basis. The mucosa-associated lymphoid tissue of the 
bowel is regulated by unique mechanisms, as reflected in oral 
tolerance, physiologic inflammation, and intraepithelial lym-
phocytes that respond to alternative pathways of activation. 
Moreover, the existence of novel antigen-presenting cells is 
responsible for distinct immune responses.
Altered immune responses are considered to be quite 
important elements related to the pathogenesis of IBD. The 
innate immune system plays a significant role in the defense 
mechanisms by recognizing bacterial products and cellular 
signaling. The abnormal signaling pathways can lead to dys-
regulation of the inflammatory response. Impairment of this 
system results in activation of the adaptive immune system 
leading to excessive proinflammatory cytokine production 
derived from CD4+ T cells over and above the response nor-
mally associated with tolerance and immunoregulation.2
Intestinal epithelial cell barrier function is also considered 
to be an important part of the immune defense of the host. 
Inappropriate access of antigens to the mucosal immune 
system through dysfunctional barrier function represents an 
important element in the IBD pathophysiology.
Genetic predisposition affects the regulation of innate 
and adaptive immunity. Therefore, immunogenetic pathways 
associated with innate and adaptive immunity, cytokines 
secreted by innate and adaptive immune cells, epithelial and 
leukocyte factors, and structures on the endothelium that 
regulate the recruitment of leukocytes define pathways that 
could be therapeutic targets.
There are some differences between CD and UC in the 
underlying immunological disturbances. In CD the antigen pre-
senting cells and macrophages produce mainly interleukin-12 
(IL-12) and IL-18 resulting in a Th1-type polarization and 
production of pro-inflammatory cytokines including tumor 
necrosis factor-α (TNF-α), interferon-γ (IFN-γ), and IL-2. 
Subsequently these cytokines stimulate the antigen   presenting 
cells to secrete other cytokines including IL-1, IL-6, IL-8, 
IL-12, and IL-18, thus leading to a self-sustained cycle.3
Patients with UC exhibit an added contribution of Th2 
responses characterized by increased secretion of IL-4, IL-5, 
and IL-13 and reduced amounts of IFN-γ. Th17 cells were 
identified as a new subset of T helper cells unrelated to Th1 
or Th2 cells. Th17 cells differentiate under the influence of 
IL-1β, IL-6, IL-21 and IL-23.4 Recently it was shown that 
transforming growth factor-β (TGF-β) regulates also the 
differentiation of Th17 cells, with the presence of cytokines 
favoring Th17 cell differentiation.5
Additionally, other molecules involved in leukocyte 
  trafficking (adhesion molecules), chemokines, and tis-
sue repair molecules are also crucial in the pathogen-
esis of the disease. In IBD continuous production of 
pro-  inflammatory cytokines results in an inappropriately 
increased adhesion molecule expression, as well as in an 
aberrant expression of molecules not normally expressed by 
specific lymphocyte subpopulations.6
In recent years the knowledge of all these complex 
pathophysiological processes has resulted in the implemen-
tation of a number of different pharmaceutical agents in the 
treatment of IBD. These drugs were designed to minimize the 
inflammatory process through inhibition of different targets.
In this review we will try to describe the established and 
emerging therapeutic strategies in patients with IBD.
Drugs currently in use in patients 
with IBD
Conventional therapies remain the cornerstone of treatment 
for the majority of patients with IBD, only a proportion of 
whom require biologic therapies. During recent years atten-
tion has been given to the optimization of conventional and 
biologic IBD therapies. Newer mesalazine formulations with 
a reduced pill size and only one dose per day demonstrate 
similar efficacy to older formulations. New corticosteroids 
(CSs) retain the efficacy of older CSs while exhibiting a 
higher safety profile. The role of antibiotics and probiot-
ics has been further clarified. Finally, significant progress 
in understanding thiopurine metabolism has improved the 
effective dose along with adjunctive therapies.
Table 1 shows the drug categories currently used in the 
treatment of patients with IBD.
Anti-inflammatory drugs
Mesalazine
Mesalazine, the active moiety of sulfasalazine, is available in 
specially formulated oral and rectal forms for the treatment of Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
187
Current and emerging drugs for IBD
active UC of mild to moderate severity and for maintenance 
therapy during disease remission.
The new preparations of mesalazine offer convenience 
and high dosage, while retaining their safety. New dosage 
regimens are likely to become standard practice in the near 
future. The drug might also act as a chemopreventive agent 
of colorectal cancer in the context of IBD, probably via the 
agonism of the peroxisome proliferator-activated receptor-γ 
(PPAR-γ). In future, even more effective agents based on 
mesalazine are expected, based on more powerful agonism 
of PPAR-γ. Mesalazine, either in tablets coated with acrylic-
based resin or microgranules coated with ethylcellulose can 
be delivered to the distal small intestine and colon.7
Mesalazine in ulcerative colitis
Orally administered mesalazine represents an effective drug 
in the treatment of patients with mild to moderate active 
distal UC and for maintaining remission. In cases of distal 
UC mesalazine can also be administered rectally as a sup-
pository, enema, or foam.8
Oral mesalazine in a dose of 1.5 to 2.4 g daily has similar 
efficacy to sulfasalazine 2 to 3 g daily in patients with mild to 
moderate UC. Mesalazine enemas once a day are more effective 
than placebo and apparently similar to enemas of prednisone 
25 mg or oral sulfasalazine 3 g. Mesalazine 4 g enemas are more 
effective than enemas containing hydrocortisone 100 mg.
Once-daily dosing of delayed-release mesalazine at doses 
of 1.6 to 2.4 g/day was shown to be as effective as twice-daily 
dosing for maintenance of clinical remission in patients with 
UC, thus increasing the compliance of the patients.9
Balsalazide disodium 1.1 g tablets administered as 3.3 g 
twice daily are effective, well-tolerated, and significantly 
better than placebo for improving signs and symptoms of 
mild-to-moderately active UC.10 Again, this new formula-
tion is expected to significantly improve convenience and 
compliance of patients with active UC.
The ASCEND I study showed that delayed-release oral 
mesalazine is an effective and well-tolerated therapy in 
patients with mildly to moderately active UC, and a 4.8 g/day 
dose (Asacol® HD, 800-mg tablet; Procter and Gamble, 
Pharmaceuticals, Inc, Mason, OH) may improve treatment 
success in patients with moderate disease compared with 
mesalazine 2.4 g/day (Asacol, 400-mg tablet).11
The ASCEND III study was designed to determine the 
efficacy and safety of mesalazine 4.8 g/day (Asacol HD, 
800-mg tablet) compared with 2.4 g/day (Asacol, 400-mg 
tablet) in moderately active UC. The results showed that 
70% of patients who received 4.8 g/day achieved treatment 
success at week 6, compared with 66% of patients receiving 
2.4 g/day.12
In a study aiming to determine the therapeutic equiva-
lence and safety of once daily versus 3 times daily dosing 
of a total daily dose of 3 g mesalazine granules (Salofalk®, 
Dr Falk Pharma GmBH, Freiburg, Germany) in patients 
with active UC it was shown that once daily 3 g mesalazine 
granules are as effective and safe as a three times daily of 
1 g schedule.13
Most patients with mild-to-moderate UC who fail to 
achieve remission with up to 8 weeks’ initial mesalazine 
therapy could achieve clinical and endoscopic remission 
following a further 8 weeks’ treatment with high-dose 
MMX technology (Multi Matrix System) mesalazine therapy 
(Mezavant® tablet 1.2 g; Shire, Dublin, Ireland).14
Two phase III studies have evaluated mesalazine with 
MMX technology in patients with active mild-to-moderate 
UC and shown it to be effective regardless of disease extent 
and severity, gender, and previous low-dose mesalazine 
therapy.15
Conclusion
Mesalazine is an effective drug in the treatment of mild-to-
moderately active distal UC at a dose of 2.4 to 4.8 g/day. 
Once daily dosing should be the preferred application mode 
in active UC. The drug is generally well tolerated with few 
side-effects reported. However, patients must check their 
renal function at 6-month intervals. Mesalazine can also 
be tolerated by 85% of patients allergic to or intolerant of 
  sulfasalazine. Side-effects of mesalazine enemas are confined 
to local irritation.16
Mesalazine in Crohn’s disease
A recent meta-analysis evaluated the efficacy of aminosalicy-
lates compared with placebo, CSs, and other aminosalicylates 
in active CD.17
Table 1 Established drug categories used in the treatment of 
inflammatory bowel disease
Drug group Drugs
Anti-inflammatory • Mesalazine
•   Corticosteroids (prednisolone, 
methylprednisolone, butesonide)
Immunosuppressives •   Azathioprine, 6-mercaptopurine, 
methotrexate, cyclosporin, tacrolimus
Antibiotics •   Metronidazole, ornidazole, clarithromycin, 
rifaximin ciprofloxacin, anti-TB
Probiotics
Biologics • Infliximab, adalimumab, certolizumab pegol
Abbreviation: TB, tuberculosis.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
188
Triantafillidis et al
The results revealed that sulfasalazine was superior to 
placebo in inducing remission, with benefit confined mainly to 
patients with colitis, although it was less effective than CSs.
Low-dose mesalazine (1–2 g/day) did not differ from 
placebo and was less effective than CSs, while high-dose 
mesalazine (3–4.5 g/day) was not superior to placebo for 
induction of remission or response. Mesalazine could also 
be less effective than budesonide.17
Prevention of relapses in patients operated on for CD 
represent a rather difficult task. In a trial aiming to compare 
azathioprine (AZ) with mesalazine for the prevention of 
recurrence in patients with postoperative CD, AZ did not 
show better results than mesalazine.18
Conclusion
The available data do not support a role for mesalazine in 
the treatment of active CD.
Corticosteroids
CSs suppress inflammation by blocking the early manifesta-
tions of inflammation, including enhanced vascular permeabil-
ity, vasodilation, and infiltration by neutrophils as well as the 
later consequences of inflammation, including fibroblast acti-
vation, vascular proliferation, and deposition of collagen. CSs 
also influence immunological responses such as T-responses to 
antigens, downregulate production of inflammatory cytokines, 
and interfere with nuclear factor-κB (NF-κB) production, 
thereby blunting inflammatory response.19
CSs can be administered orally, in the form of enemas, 
or systematically in conjunction with or without other drugs. 
The most widely used CSs are prednisolone, methylpredni-
solone, and budesonide.
Corticosteroids in ulcerative colitis
The dose and route of administration of CSs in active UC 
depends on the severity of the disease and ranges from 20 to 
40 and 50 to 60 mg/day for moderate and severe flare-ups, 
respectively. Subsequently, the dose should be reduced by 
10 or 5 mg/week depending on the clinical and endoscopic 
remission.20 In severe cases CSs should be given parenterally 
for at least 10 days. If there are no clinical or laboratory signs 
of improvement the patient must be treated with cyclosporin 
or biologic agents. CSs are not useful for maintenance treat-
ment of UC.
Budesonide is an enteric-coated, locally acting CS, 
whose pH- and time-dependent coating enables its release 
into the ileum and ascending colon. There is no evidence 
to   recommend the clinical use of oral budesonide for the 
induction of remission in active UC.21
Corticosteroids in Crohn’s disease
CSs are highly effective drugs for induction of remission in 
patients with active CD. The various formulations of CSs 
can induce fast remission, improving most of the symptoms 
in a few days, although they cannot achieve mucosal heal-
ing and they have a number of side-effects. In a Cochrane 
meta-analysis CSs were highly significantly more effective 
than placebo and mesalazine in inducing remission. It should 
be emphasized that although CSs cause more adverse events 
than either placebo or low-dose mesalazine, these adverse 
events did not lead to increased study withdrawal.22 Some 
patients could become steroid-dependend or steroid resistant. 
CSs are not useful for maintenance treatment of CD.
Budesonide treatment for up to 1 year is well tolerated, 
with an adverse-event profile similar to that of placebo.22 
The 1-year relapse rates are low and not significantly differ-
ent between patients treated with budesonide 6 mg versus 
9 mg/day. Time to relapse and the number of adverse events 
are similar in both groups.14 Budesonide may be a safe option 
for treatment of CD during pregnancy.23
Conclusion
CSs remain the cornerstone of initial therapy in both 
active CD and active UC. One-third of patients will fail 
to respond. Subsequent management of this proportion of 
patients involves decisions on whether to use cyclosporin 
or infliximab without compromising the health or safety of 
the patient, or to offer surgical treatment. Further studies 
are required in order to determine the optimal duration of 
treatment and tapering protocol as well as whether CSs are 
more effective in patients with certain phenotypes.
Immunosuppressives
Immunosuppressives are a group of drugs acting by inhibit-
ing proliferation and activation of lymphocytes. In recent 
years the experience with AZ, 6-mercaptopurine (6-MP), 
methotrexate, cyclosporin, and tacrolimus has increased 
  considerably. AZ is a prodrug that is converted to 6-MP. 
Subsequently 6-MP can be metabolized by thiopurine 
methyltransferase to an inactive metabolite, 6-methylmer-
captopurine, or can be anabolized to two active metabolites, 
6-thioguanine and 6-methylmeracaptopurine ribonucleotides. 
The   therapeutic efficacy and the side-effects of AZ are related 
to the serum levels of 6-thioguanine. A genetic polymorphism Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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for   thiopurine methyltransferase influences its activity. Low 
levels of thiopurine methyltransferase activity are associated 
with increased levels of 6-thioguanine, thus increasing both 
therapeutic efficacy and toxicity.
Azathioprine and 6-mercaptopurine
The optimal dose of AZ is 2 to 2.5 mg/kg bodyweight and of 
6-MP 1 to 1.5 mg/kg bodyweight. The favorable results of 
the drug could appear after several (12 or more) weeks.
A recent analysis of eight randomized trials revealed that 
AZ and 6-MP were effective for inducing remission in active 
CD. Treatment longer than 17 weeks resulted in a better 
outcome. A steroid sparing effect was also seen. Adverse 
events requiring withdrawal from a trial were increased with 
active therapy.24
AZ and 6-MP are considered to be effective in approxi-
mately 40% of IBD patients after 5 years of treatment. 
According to recent data, one-quarter of the patients discon-
tinued the drugs within 3 months, due to adverse events. If 
the results are favorable in the first months, the use of AZ 
could be extended over many years.25 It must be stressed 
that AZ withdrawal is associated with a high risk of relapse. 
If AZ is well tolerated, it should not be interrupted.26 Most 
experts agree that the concurrent use of mesalazine and 
AZ as induction or maintenance treatment in patients with 
IBD is justified. According to recent data the concomitant 
use of aminosalicylates and AZ offer much benefit to the 
patient.27
Methotrexate
Experience with methotrexate is much less than with AZ. 
It can be used in patients with steroid-dependent or steroid-
refractory CD for induction as well as maintenance of 
  remission.28 Optimal dose and mode of application are still a 
matter of debate. The usual dose is 25 mg/week for induction 
and 15 to 25 mg/week for maintenance of remission, both 
applied subcutaneously (sc) or intramuscularly.29
In everyday clinical practice methotrexate is used mainly 
in patients who have failed treatment with AZ or who are 
intolerant to AZ and 6-MP. The effectiveness of the drug in 
fistulizing CD is weak. An old study did not prove that metho-
trexate is efficacious in UC patients.30 Current guidelines do 
not recommend its use in patients with UC.
Tacrolimus
Tacrolimus is a calcineurin inhibitor that suppresses pro-
inflammatory cytokine production and T-cell activation. Side 
effects, such as nephrotoxicity, are dose-dependent although 
reversible with dose reduction or cessation of therapy.
The drug has been used in patients with fistulizing CD 
and refractory UC. Long-term administration seems to be an 
effective and well-tolerated treatment for patients with refrac-
tory UC.31 However, the reported results should be interpreted 
with caution due to the small number of patients treated. 
Topical tacrolimus has also been used to treat pyoderma 
gangrenosum and ulcerative proctitis with good results.32
In general, tacrolimus is a well-tolerated and useful 
drug that should be considered as an alternative agent in the 
treatment of IBD, especially in those who are intolerant or 
refractory to conventional immunosuppressives.33 However, 
more data are needed to determine the long-term efficacy and 
safety of tacrolimus.
Cyclosporin
Cyclosporin is a powerful immunosuppressive drug mainly 
used for the prevention of rejection in transplant patients. 
The drug has been used in patients with severe flare-ups of 
UC not responding to conventional treatment. Treatment with 
intravenous (iv) cyclosporin helps to avoid colectomy in a 
substantial proportion of patients with severe UC.34 In a rel-
evant study in which iv cyclosporin at a dose of 5 mg/kg was 
administered to 18 patients with fulminant UC, 83% of 
patients responded to treatment. On follow-up at 2, 6, 12, 
and 24 months, the colectomy-free rates were 72%, 67%, 
61%, and 56%, respectively.35
The mechanisms of action of the drug are not yet fully 
understood. Cyclosporin was shown in experimental colitis 
to upregulate the expression of TGF-β in the colonic tissue, 
enhance the expression of p-Smad2 and cFLIP in epithelial 
cells, and inhibit caspase-8 activity, concurrently protecting 
from epithelial apoptosis associated with upregulation of 
TGF-β-related signaling.36
The adverse events are mild in most patients. However 
some adverse effects could be dangerous. The clinician 
must always follow up the patient appropriately by checking 
regularly drug serum levels.
Side-effects of immunosuppressives
In clinical practice AZ or 6-MP are not effective in one-third 
of patients. Up to 20% of patients discontinue therapy due to 
side-effects. Monitoring side-effects of immunosuppressives 
is mandatory for physicians treating IBD patients.
Thioguanins may have severe side-effects, the most impor-
tant being various gastrointestinal symptoms,   hepatotoxicity, Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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and pancreatitis. Nodular regenerative hyperplasia is another 
important side-effect especially in men with CD after ileoce-
cal resection. Methotrexate can induce myelosuppression, 
pulmonary fibrosis, and hepatic injury. Five milligrams of 
folic acid per week decreases gastrointestinal side effects 
without interfering with drug efficacy. Cyclosporin can 
cause renal dysfunction, tremor, hirsutism, hypertension, 
gum hyperplasia as well as gastrointestinal side-effects such 
as diarrhea, nausea, vomiting, hepatic disease, and, rarely, 
gastritis, and peptic ulcer.37
A trial of 6-MP should be considered in AZ intolerance, 
as half the patients tolerate a switch to 6-MP. Patients with 
hepatotoxicity or arthralgias and myalgias during AZ treat-
ment might benefit more often than those with other types of 
adverse events.38 Allopurinol has been shown to reduce the 
metabolism of both AZ and 6-MP. The drug has been used 
along with reduced-dose thiopurine in an attempt to avoid 
adverse drug reactions.39
Conclusion
AZ and 6-MP are effective drugs for inducing remission in 
patients with active CD as well as for the maintenance of 
remission. The rate of response increases after 17 weeks of 
therapy. Recent data support the safety of AZ and 6-MP use in 
pregnancy and lactation. Thiopurine therapy in IBD is associ-
ated with an increased risk of lymphoproliferative disorders. 
AZ and 6-MP remain among the mainstays of IBD therapy.
Antibiotics
The rationale for using antibiotics in the treatment of IBD is 
based on the assumption that intestinal bacteria are involved 
in the pathogenesis of the disease. The terminal ileum and 
large bowel represent the areas most frequently affected by 
IBD and concurrently represent the sites with the highest 
bacterial concentrations. Pouchitis seems to be associated 
with bacterial overgrowth and dysbiosis.
Enteric flora is altered in patients with IBD and enteric 
bacteria can be found within the inflamed mucosa. There are 
indications suggesting that immunological tolerance to com-
mensal bacteria has been lost in patients with IBD. Increased 
numbers of bacteroides, Escherichia coli, and enterococci, 
and decreased numbers of lactobacilli and bifidobacteria have 
been found in IBD patients. Finally, strong evidence from 
animal models suggests that the development of colitis is 
impossible in the absence of normal enteric flora. All these 
data support the assumption that manipulation of intestinal 
microbiota flora, with either antibiotics or probiotics, could 
be of benefit in patients with IBD.
Early studies claimed that a decrease in the mucosal 
  peptide antibiotics (defensins) could be involved in the 
pathogenesis of IBD. Defensins are antimicrobial peptides 
produced at a variety of epithelial surfaces. Their main func-
tion is to maintain a balance between protection from patho-
gens and tolerance to normal flora. It has been suggested that 
attenuated expression of defensins compromises host immu-
nity, thus altering the balance in favor of inflammation. This 
deficient induction may be due to changes in the intracellular 
transcription by NF-κB and the intracellular peptidoglycan 
receptor NOD2.40 The beneficial effect of antibiotics in 
CD patients supports the assumption of the existence of an 
impaired mucosal antibacterial activity.41 However, recent 
reports suggest that defensin deficiency might be a conse-
quence of mucosal surface destruction due to inflammatory 
process rather than a primary event, indicating that reduced 
defensin expression represents a consequence of the disease 
and not the real cause.42 Additional research is required in 
order to further clarify this interesting subject.
Antibiotics in ulcerative colitis
To date, relatively few trials on the use of antibacterial agents 
in UC patients have been carried out. Despite the fact that the 
results of these studies are not conclusive most clinicians have 
used antibiotics as an adjuvant therapy for severe UC.
Older studies showed that iv metronidazole in conjunction 
with CSs produced no better results compared with placebo 
plus CSs in inducing remission in patients with severe UC.43 
It was reported that 74% of patients with acute relapse 
of UC who received CSs plus oral tobramycin achieved 
complete symptomatic remission while significantly fewer 
(43%) patients who received CSs plus placebo achieved 
remission.44
Ciprofloxacin has also been tried in patients with UC 
with disappointing results.45 In order to overcome the dis-
advantages of their previous study on the route, duration, 
and dose of ciprofloxacin, the same authors described that 
iv ciprofloxacin was not effective as an adjunctive treatment 
to CSs in severe UC.46
Rifaximin was also investigated in patients with mod-
erate-to-severe active UC refractory to steroid   treatment. 
Patients received either rifaximin 400 mg twice daily or 
placebo for 10 days as an adjunct to steroid treatment. 
No significant differences in clinical efficacy were found, 
although rifaximin significantly improved stool frequency, 
rectal bleeding, and sigmoidoscopic score.47
Two recently published studies have reported that com-
bination treatment with antibiotics offers significant benefit Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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in patients with active UC. In the first study the authors 
enrolled 25 patients. Patients received amoxicillin 500 mg 
three times daily, tetracycline 500 mg three times daily and 
metronidazole 250 mg three times daily for 2 weeks as well 
as conventional treatment. At 3 and 12 months after antibiotic 
treatment, clinical activity indexes, and endoscopic and his-
tological scores were significantly decreased compared with 
those before treatment. The clinical response rates in steroid-
dependent patients were 60% and 73.3% at 3 and 12 months, 
respectively, and 50% at 12 months in steroid-refractory 
patients. Among the steroid-dependent or refractory patients, 
70.6% discontinued steroid therapy at 12 months. No serious 
drug-related toxicities were observed.48 In the second trial the 
authors investigated whether antibiotic combination induces 
and/or maintains remission of active UC. Patients with mild-
to-severe relapsing UC were assigned to oral amoxicillin 
1500 mg/day, tetracycline 1500 mg/day, and metronidazole 
750 mg/day, versus placebo, for 2 weeks, and then followed 
up. This 2-week triple antibiotic therapy produced improve-
ment, remission, and steroid withdrawal in active UC more 
effectively than the placebo.49
It seems that the subject of the role of antibiotics in UC 
is still open and further studies are required to better clarify 
their role in both active and inactive UC.
Antibiotics in Crohn’s disease
During recent years an increased amount of research has 
been published on the use of broad-spectrum antibiotics in 
CD patients. The antibiotics used so far in patients with CD 
include metronidazole, ornidazole, ciprofloxacin, tobramycin, 
clarithromycin, cotrimoxazole, and anti-TB treatment.
Metronidazole
Metronidazole has been investigated from the early 1970s. 
In a study conducted to test the efficacy and safety of the 
drug in CD patients, it was found that there was no differ-
ence between metronidazole and placebo-treated patients 
although a positive trend in favor of metronidazole was 
observed in patients with Crohn’s colitis.50 In the National 
Cooperative Swedish Study, metronidazole was compared 
with sulfasalazine as a primary treatment for CD. Although 
no significant difference was found between the two groups, 
metronidazole was effective in patients who fail to respond 
to sulfasalazine.51
In another study, metronidazole was used either as a 
single therapy or in combination with cotrimoxazole and 
compared with cotrimoxazole alone and a double placebo in 
patients with a symptomatic relapse of CD. After 4 weeks’ 
treatment there was no difference in response among the 
three treatment groups.52 In a subsequent study treatment 
with metronidazole for 16 weeks significantly decreased the 
CDAI, but no difference was found in the rates of remission 
compared with placebo.53
The potential for metronidazole 10% ointment to exert 
therapeutic benefit in perianal CD was recently evaluated. 
Patients received metronidazole 10% ointment, 0.7 g applied 
perianally three times daily, or placebo ointment. The mean 
reduction in perianal CD activity index score at 4 weeks 
did not differ between the two groups. However, more 
patients in the metronidazole group showed a reduction 
in Pediatric Crohn’s Disease Activity Index of at least 
five points compared with the placebo group. Perianal 
discharge and perianal pain both declined significantly in the 
metronidazole-treated patients. Metronidazole 10% ointment 
was well tolerated, with minimal adverse effects. It could be 
used as a potential treatment for pain and discharge associated 
with perianal CD.54
Metronidazole has also been used in combination with 
other antibiotics. An antibiotic combination including 250 mg 
metronidazole four times daily plus 500 mg ciprofloxacin 
twice daily was compared with a standard steroid treatment 
for 12 weeks. The 2 treatments showed similar rates of remis-
sion, suggesting that this combination is a potential alterna-
tive to steroid treatment in the acute phase of CD.55 In another 
trial the combination of metronidazole and ciprofloxacin 
was supplemented with budesonide (9 mg/day) for active 
CD. No difference was noticed compared with placebo, but 
the overall response in the two groups was lower than that in 
previous studies using budesonide, suggesting that antibiotic 
treatment is more effective in colonic disease than in isolated 
small bowel involvement.56
Unfortunately, the systematic administration of metron-
idazole is accompanied by important side-effects, including 
nausea, anorexia, dysgeusia, dyspepsia, and peripheral 
neuropathy, which limit its use in approximately 20% of 
patients.
Ornidazole
Ornidazole is a nitroimidazole derivate with a similar chemi-
cal structure and antimicrobial properties to metronidazole. 
Initially the efficacy of the drug was tested in a small   number 
of patients with active CD.57 In a subsequent study, 25 
patients with active CD received 500 mg/day of ornidazole 
for 4 weeks.58 The results showed that the Crohn’s Disease 
Activity Index (CDAI) declined significantly from week 0 
to week 4, while the number of patients going into remission Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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increased gradually from week 0 to week 4. Presence and 
severity of abdominal pain decreased and bowel movements 
were reduced. General well-being improved significantly. 
An increase in bodyweight was noticed at the end of the 
fourth week. The drug also seems to reduce the recurrence 
rate,59 while being quite safe.60 In normal subjects ornidazole 
reduces the levels of serum C3.61
Ciprofloxacin
Ciprofloxacin has been extensively used in patients with active 
CD with or without perineal involvement. In a study comparing 
ciprofloxacin 500 mg twice daily with placebo twice daily for 
6 months, the administration of ciprofloxacin significantly 
reduced CDAI score compared with placebo.62 In another 
study patients with a mild-to-moderate flare-up of CD were 
randomized to receive ciprofloxacin 1 g/day or mesalazine 
(Pentasa®; Shire) 4 g/day for 6 weeks. Complete remission was 
observed in 56% of patients treated with ciprofloxacin and in 
55% of those treated with mesalazine.63 In an open study 72 
patients with active CD were treated with ciprofloxacin 500 mg 
twice daily and metronidazole 250 mg three times daily for 
10 weeks. Clinical remission was observed in 68% of patients, 
and 76% showed clinical response.64
The drug has also been used in patients with   fistulizing 
disease. In a relevant study, 25 patients with CD and actively 
draining perianal fistulas received ciprofloxacin 500 mg, 
metronidazole 500 mg, or placebo twice daily for 10 weeks. 
Remission and response was more frequent in patients 
treated with ciprofloxacin although the differences were not 
significant.65
Ciprofloxacin is an effective drug in a proportion of 
patients with active CD mainly located in the colon.
Clarithromycin
Clarithromycin is a broad-spectrum antibiotic that has good 
penetration into macrophages. Clarithromycin 1 g for 3 months 
was found to be ineffective in active CD although benefit was 
observed during the first month, suggesting that an initial effect 
may be attenuated by subsequent bacterial resistance.66
Rifaximin
Rifaximin is a rifamycin analog with a broad spectrum of 
activity. The drug has been used mainly on intestinal infec-
tions because it is an almost non-absorbed antibiotic from 
the gastrointestinal tract.
In an open-label study on the efficacy and safety 
of rifaximin 600 mg/day for 16 weeks in patients with 
  mild-to-moderate active CD, 59% of patients were in 
  remission at the end of the study, with a significant reduction 
of the mean CDAI score compared with baseline.67
In another study patients with mild-to-moderate CD 
were randomized to three treatments for 12 weeks: rifaximin 
800 mg once daily plus placebo, rifaximin 800 mg twice 
daily, and placebo twice daily. Remission and response rates 
of rifaximin 800 mg twice daily were significantly higher than 
those of placebo and rifaximin 800 mg once daily in patients 
with elevated C-reactive protein (CRP) values. Rifaximin 
800 mg twice daily was superior to placebo in inducing 
clinical remission.68
A recent experimental study suggested that the preventive 
and therapeutic role of rifaximin on IBD is probably achieved 
through human pregnane X receptor-mediated inhibition of 
the NF-κB signaling cascade.69
Anti-TB treatment
It has been suspected that Mycobacterium avium subsp. 
paratuberculosis, which causes Johne’s disease, might also 
be a cause of CD.
In a prospective, parallel, placebo-controlled, double-blind, 
randomized trial of 2 years duration, 213 patients with active 
CD were randomized to clarithromycin 750 mg/day, rifabutin 
450 mg/day, clofazimine 50 mg/day or placebo, in addition to 
a 16-week tapering course of prednisolone. At week 16, there 
were significantly more subjects in remission in the antibiotic 
arm (66%) than the placebo arm (50%). During the following 
year, no significant differences between antibiotic and placebo 
groups were noticed. The findings of this study do not support 
a significant role for M. avium subsp. paratuberculosis in the 
pathogenesis of CD in most patients.70
Prevention of postoperative recurrence by antibiotics
Antibiotics have also been studied in the prevention of 
postoperative disease recurrence of CD. Sixty patients were 
randomized to receive either metronidazole or placebo for 
12 weeks. Metronidazole significantly reduced the incidence of 
severe endoscopic relapse and clinical recurrence rate.71 More 
recently, ornidazole used continuously for 1 year was shown 
to be more effective than placebo in the prevention of clinical 
and endoscopic recurrence in the neoterminal ileum.72
A recent study investigated whether metronidazole for 
3 months together with AZ for 12 months was superior to 
metronidazole alone in reducing recurrence of postopera-
tive CD in high-risk patients. Despite the enhanced risk of 
recurrence, the overall incidence of significant recurrence 
was rather low, probably owing to metronidazole treatment. 
Concomitant AZ resulted in lower endoscopic recurrence Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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rates and less severe recurrences.73 Therefore this combined 
treatment seems to be reasonable for postoperative CD 
patients with an enhanced risk for recurrence.
Conclusion
The results of reported studies suggest that antibiotics 
are useful in the treatment of patients with CD. According 
to the opinion of many experts, incorporation of antibiotics 
into the therapeutic armamentarium for CD either as first-line 
therapy or in combination with immunosuppressive drugs 
might be a rational strategy.74 This assumption is further sup-
ported by the results of a recent meta-analysis which showed 
that long-term treatment with nitroimidazoles or clofazimine 
are effective in patients with CD.75
However significant questions remain to be answered. 
Why are only a small number of antibiotics useful in patients 
with IBD? What is the exact mode of action of metronidazole 
and ciprofloxacin? What is the role of concurrent infection 
(eg, Yersinia enterocolitica) in the course of CD? (We must bear 
in mind that ciprofloxacin is an effective drug against Yersinia 
spp.). In the near future, the answers to these questions could 
result in a more etiological therapeutic approach.
Probiotics
Probiotics are live non-pathogenic microorganisms adminis-
tered to improve microbial balance in the gastrointestinal tract. 
They consist of Saccharomyces boulardii yeast or lactic acid 
bacteria, such as Lactobacillus and Bifidobacterium spp.
Probiotics exert their beneficial effects through various 
mechanisms, including reduced intestinal pH, decreased 
colonization and invasion by pathogenic organisms, and 
modification of the host immune response. Lactobacillus 
paracasei significantly decreases the plasma and lymphocyte 
content of proinflammatory cytokines in patients with UC.76 
S. boulardii-secreted protein(s) inhibit production of proin-
flammatory cytokines by interfering with the global mediator 
of inflammation NF-κB, and modulating the activity of the 
mitogen-activated protein kinases ERK1/2 and p38. It has 
also some other interesting properties, including activation of 
expression of PPAR-γ, suppression of ‘bacteria overgrowth’ 
and host cell adherence, release of protease that cleaves 
Clostridium difficile toxin A, and stimulation of antibody 
production against toxin A.77
We must bear in mind, however, that probiotic benefits 
associated with one species or strain do not necessarily hold 
true for others. Also there is no consensus about the number 
of microorganisms that must be ingested to obtain a beneficial 
effect; however, a probiotic should typically contain several 
billion microorganisms to increase the chance of adequate 
gut colonization.78
Probiotics in ulcerative colitis
The administration of probiotics in patients with UC seems 
to be quite beneficial. The induction of remission in patients 
with active distal UC by E. coli Nissle (EcN) administered in 
the form of enemas was investigated in a recent clinical trial. 
Patients were assigned to treatment with 40, 20, or 10 mL 
enemas containing 10E8 EcN/mL or placebo once a day 
for 2 weeks. In the intention-to-treat analysis the number of 
responders was not significantly higher in the EcN group than 
in the placebo group, although the efficacy of rectal EcN was 
significant in the per-protocol analysis.79 The results support 
EcN as a well-tolerated alternative treatment in moderately 
active distal UC.
The use of probiotics in UC patients to maintain remission 
seems to be promising. VSL#3® (Sigma-Tau Pharmaceutics, 
Inc, Gaithersburg, MD) was shown to be a safe and effective 
modality in achieving clinical responses and remissions in 
patients with mild-to-moderately active UC.80 In a relevant 
study it was reported that the decrease in UC activity index 
scores (UCDAI) of 50% or more was significantly higher 
in the VSL#3 group than in the placebo group (63.1 versus 
40.8). Significant improvement with VSL#3 in the UCDAI 
score and the degree of rectal bleeding was recorded. Remis-
sion rate was significantly higher in the VSL#3 group than in 
the placebo group (47.7% versus 32.4%). VSL#3 supplemen-
tation seems to be safe and able to reduce UCDAI score in 
patients with relapsing mild-to-moderate UC who are under 
treatment with mesalazine and/or immunosuppressants.81
Rembacken et al investigated whether the administra-
tion of a non-pathogenic strain of EcN was as effective as 
mesalazine in preventing relapse of UC as well as whether 
the addition of E. coli to standard medical therapy increased 
the rate of remission of active UC. The results showed that 
75% of patients in the mesalazine group achieved remission 
compared with 68% in the E. coli group. In the mesalazine 
group, 73% of patients relapsed compared with 67% in the 
E. coli group (no significant differences).82 They concluded 
that treatment with a non-pathogenic E. coli is equally effec-
tive as mesalazine in maintaining remission of UC.
Lactobacillus rhamnosus GG strain alone or in com-
bination with mesalazine decreased the relapse rate and 
significantly increased time to relapse compared to mesala-
zine alone. Bifidobacteria-fermented milk-supplemented 
patients with UC had significantly fewer exacerbations than 
  non-supplemented patients.83Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Probiotics in Crohn’s disease
CD is characterized by increased intestinal permeability that 
permits antigen penetration into the intestinal tissue. In CD 
patients in remission, S. boulardii added to baseline therapy 
may improve the intestinal permeability.84 So far, none of the 
probiotics tested has been shown to be effective in induction of 
remission or in maintenance of remission in patients with CD.
Probiotics in pouchitis
Probiotics are probably useful in inducing remission in active 
pouchitis. In a Cochrane systematic review it was suggested 
that oral probiotic therapy with VSL#3 appears to be an effec-
tive therapy for maintaining remission in patients with chronic 
pouchitis in remission.85 However, because of the small number 
of patients tested the results must be interpreted with caution.
A multispecies probiotic mixture of eight strains seems to be 
helpful in maintaining remission in patients with pouchitis.86
Conclusion
Although probiotics are considered to be well tolerated, 
some adverse events, mainly bloating and flatulence, can 
occur. They should be used cautiously in patients who are 
critically ill or severely immunocompromised or in those 
with central venous catheters, since systemic infections may 
rarely occur.87 Administration of bacteria-derived probiot-
ics should be separated from antibiotics by at least 2 hours. 
Because of the relatively small number of published trials, 
questions about optimal probiotic, optimal dosing, and 
specific patient populations to maintain remission remain 
to be answered.
Biologic agents
Tumor necrosis factor alpha blocking strategies
Because anti-TNF-α plays a pivotal role in the process of the 
inflammation in IBD patients, inhibition of this cytokine is 
expected to be a powerful treatment strategy in patients with 
both CD and UC. The available anti-TNF-α factors include 
infliximab, adalimumab, and certolizumab pegol. All these 
factors have been approved for use in the United States; 
however only the first two are licensed for use in Europe. 
All major gastroenterological associations recommend that 
treatment with anti-TNF-α monoclonal antibodies be con-
sidered in patients with moderate-to-severe CD refractory to 
concomitant aminosalicylates, CSs, or immunosuppressives, 
or patients who have contraindications to, or poor tolerance 
of, these agents. Infliximab has also been approved for the 
treatment of patients with severe UC not responding to 
  conservative treatment.
Infliximab
Infliximab (IFX) has successfully been used in patients with 
CD or UC (Table 2).
Infliximab in Crohn’s disease
IFX is an immunoglobulin G1 (IgG1) type chimeric mono-
clonal antibody against TNF-α which acts by binding to 
circulating and membrane-bound TNF-α, inducing a cell 
mediated cytotoxic reaction and enhancing the programmed 
cell death of activated T-cells.
Studies on the use of IFX in either CD or UC are shown 
in Table 2. The ACCENT I study showed that treatment 
should be maintained in patients who responded to a single 
infusion of IFX88 and that maintenance therapy is superior 
to episodic administration while providing less anti-IFX 
antibody formation.89 Patients receiving systematic therapy 
also need fewer hospitalizations and less surgery.90
Healing of the mucosa has been shown to be a strong pre-
dictor of improved outcome of CD and anti-TNF-α therapy 
is a strong inducer of mucosal healing.91
IFX is also efficacious in fistulizing CD. In the study of 
Present et al, the primary end-point (a reduction of 50% or 
more from baseline in the number of draining fistulas) was 
achieved in 68% and 56% of patients treated with 5 and 
10 mg/kg IFX at week 0, 2, and 6, compared with 13% of the 
patients receiving placebo. The secondary end-point (closure 
of all fistulas) was achieved in 55% of the patients assigned 
to receive 5 mg/kg of IFX and 38% of those assigned to 
10 mg/kg compared with 13% of patients receiving placebo 
(P = 0.002 and P = 0.02, respectively).92
The ACCENT II study demonstrated the efficacy of IFX 
in maintaining the good results in patients with perianal and 
enterocutaneous fistulae. The median time during which the 
patients were in remission was 14 and 40 weeks in the placebo 
and IFX groups, respectively. The remission rate was 36% in 
the IFX group compared with 19% in the placebo group.93
In a recent trial, the efficacy of IFX monotherapy, AZ 
monotherapy, and the two drugs combined was tested in 508 
adults with moderate-to-severe CD. These patients had not 
undergone previous immunosuppressive or biologic therapy. 
Patients who were treated with IFX plus AZ or IFX mono-
therapy were more likely to have a corticosteroid-free clinical 
remission than those receiving AZ monotherapy.94
Timing of biological therapy is a matter of continuous 
debate. Early aggressive immunosupression seems to be the 
most efficacious therapeutic strategy in high-risk patients. In 
a meta-analysis it was found that early diagnosis, need for 
CS therapy at the first flare, and fistulizing behavior at the Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Table 2 Infliximab in either Crohn’s disease or ulcerative colitis
Study Number of patients Treatment schedule Primary end-point Response to treatment
Accent I88 n = 573 active CD 5 mg/kg single infusion  
5 or 10 mg/kg maintenance  
for those responded
CDAI . 70 points 2 weeks 
response clinical remission  
54 weeks
58%
28.3% and 38.4% respectively 
vs 13.6% of placebo
Accent II93 n = 306 
Fistulizing CD
5 mg/kg for those who responded Week 54 absence of fistulas 36%
Ruggiero160 n = 24 patients with  
ileocolonic resection
iv 5 mg/kg for 12 months  
vs placebo
Endoscopic and histologic  
recurrence at 1 year
91% and 27.3% (Infliximab)  
vs 84.6% and 84.6% (placebo)
Colombel94 n = 508 patients with  
moderate-severe CD
5 mg infliximab/kg at weeks  
0, 2, and 6 and then every  
8 weeks plus daily oral  
placebo vs 2.5 mg oral  
azathioprine/kg daily plus a  
placebo infusion vs combination  
of the 2 drugs.
Corticosteroid-free clinical  
remission at week 26
56.8% (IFX plus AZ) vs 44.4%  
(IFX + placebo) vs 30.0%  
(AZ) (significant differences)
Kohn99 n = 83 patients with  
severe UC
Infliximab 5 mg/kg iv  
(1 or more infusions)
Short-term outcome: colectomy/ 
death 2 months after the first  
infusion.
Long-term outcome: survival free 
from colectomy
15% underwent colectomy  
after first infusion (greater  
rates in patients receiving  
only 1 infusion)
ACT 1 and  
ACT 2 studies96
n = 364 patients with  
UC and Mayo score 6–12
Placebo vs infliximab (5 or  
10 mg/kg) at weeks 0, 2,  
and 6, then 5 mg/kg/8  
weeks through week 46  
(ACT 1) or through week 22  
(ACT 2)
Response: drop of Mayo .3  
rectal bleeding: 0–1 
ACT 1  
Response week 8 
Response week 54
ACT 2 
Response week 8  
Response week 30
 
 
 
69% 
45% 
 
64% 
31%
Abbreviations: AZ, azathioprine; CD, Crohn’s disease; CDAI, Crohn’s disease activity index; IFX, infliximab; UC, ulcerative colitis.
time of the diagnosis were independent risk factors for an 
unfavorable disease course.95 Extended small bowel disease, 
upper gastrointestinal involvement, and smoking, also seem 
to represent risk factors for an unfavorable course.
Infliximab in ulcerative colitis
Two randomized, double-blind, placebo-controlled studies 
(ACT 1 and ACT 2), evaluated the efficacy of IFX for induc-
tion and maintenance therapy in patients with UC. Patients 
with a Mayo score of 6 to 12 points and moderate-to-severe 
active disease on sigmoidoscopy despite concurrent treat-
ment with CSs alone or in combination with AZ or 6-MP 
in ACT 1 or despite concurrent treatment with CSs alone or 
in combination with AZ or 6-MP and mesalazine in ACT 2, 
were investigated. In ACT 1, 69% and 61% of patients who 
received 5 or 10 mg/kg of IFX had a clinical response at 
week 8, compared with 37% of those who received placebo. 
In ACT 2, clinical response at week 8 was noticed in 64% 
and 69% of patients who received 5 or 10 mg/kg of IFX 
compared with 29% of those on placebo.96
The efficacy of IFX as a rescue therapy for severe to 
moderately severe UC not responding to iv steroid therapy 
has also been documented. In a relevant study significantly 
more patients treated with placebo required colectomy by 
3 months compared with those treated with a single infu-
sion of 5 mg/kg IFX.97 Patients with moderate-to-severe UC 
treated with IFX were significantly less likely to undergo 
colectomy through 54 weeks than those receiving placebo.98 
In the short term, two or more infusions seem to be more 
effective than a single infusion.99
Adalimumab
Adalimumab (ADA) is a fully human IgG1 type anti-TNFα 
monoclonal antibody that it is administered subcutaneously.
The CLASSIC-I trial investigated the efficacy of ADA for 
induction of remission in patients with CD.100 A total of 299 
patients with moderate to severe CD naive to anti-TNF therapy 
received ADA 40 mg/20 mg, 80 mg/40 mg, or 160 mg/80 mg 
or placebo at weeks 0 and 2. The rates of remission at week 
4 in the ADA 40 mg/20 mg, 80 mg/40 mg, and 160 mg/80 mg 
groups were 18%, 24% and 36%, respectively, in comparison 
with 12% in the placebo group. It was confirmed in this study 
that the optimal induction dosing regimen for ADA is 160 mg 
at week 0 followed by 80 mg at week 2 (Table 3).Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Table 3 Adalimumab in either Crohn’s disease or ulcerative colitis
Study Number of  
patients
Duration of  
treatment
Comparisons Primary end-point Response to  
treatment
CHARM study102 n = 778 3–12 months Placebo vs adalimumab 
40 mg eow vs adalimumab 
40 mg weekly, all after an 
80 mg/40 mg adalimumab 
induction regimen
3- and 12-month 
hospitalization risks
Less rates of hospitalization 
and CD-related operations  
in adalimumab group
CLASSIC-I100 Moderate to  
severe CD  
n = 299
Adalimumab sc 160 and  
80 mg or 80 and 40 mg  
or 40 and 20 mg at  
week 0 and 2
Remission rate at  
week 4
36%
24% 
18%
CLASSIC-II101 Patients from  
Classic I 
n = 276
40 mg: week 0 and 2  
and maintenance therapy  
40 mg eow or weekly  
until week 56
Remission rates 79% 
83%
Colombel106 n = 117 56 weeks After induction treatment 
patients at week 4, were 
assigned to double-blind 
placebo or adalimumab  
40 mg eow or weekly  
to week 56
Healing of draining  
fistulas in patients  
with active CD
Mean number of  
draining fistulas/d  
significantly decreased  
in adalimumab-treated  
patients
Sandborn103 Loss of response  
to IFX  
n = 325
4-week, double-blind,  
placebo
160 mg and 80 mg at  
weeks 0 and 2
Remission at week 4 
response
21% in the adalimumab vs  
7% of placebo. 
70-point response: 52% 
in adalimumab vs 34%  
of placebo
Triantafillidis104 n = 30 Patients either naive to  
biologics or with response  
loss or intolerance to IFX
Remission in 63.3%
Clinical response in 30%
Reinisch107 n = 390 with UC 8 weeks Adalimumab (160/80 or  
80/40) vs placebo
Clinical remission 18.5% vs 9.2% (P = 0.031)  
10% vs 9.2% (NS)
Abbreviations: CD, Crohn’s disease; eow, every other week; IFX, infliximab; UC, ulcerative colitis.
The CLASSIC-II study evaluated the long-term efficacy 
and safety of ADA.101 Patients from CLASSIC-I study 
(n = 276) were included and received open-label ADA 40 mg 
at week 0 (week 4 of CLASSIC I) and week 2. Patients in 
remission at week 0 and 4 were re-randomized to ADA 40 mg 
weekly or every other week (eow) or placebo until week 56. 
Non-remitting patients were randomized to open-label 40 mg 
ADA eow Fifty-five of 276 patients achieved remission at 
week 4; 79% who received ADA 40 mg eow and 83% who 
received 40 mg weekly were in remission at week 56, versus 
44% for placebo. Of 204 patients who entered the open-label 
arm, 46% were in clinical remission at week 56. Therefore, 
these two studies revealed that ADA is able to induce and 
maintain remission in CD patients.
A larger study (CHARM) evaluated the efficacy of adali-
mumab in the maintenance of response in 854 CD patients.102 
After an open-label induction therapy with 80 mg (week 0) 
and 40 mg (week 2) patients were randomized to 40 mg ADA 
eow, 40 mg ADA weekly or placebo maintenance therapy. 
The percentage in remission was significantly greater in the 
ADA 40-mg eow and 40-mg weekly groups versus placebo 
at week 26 (40%, 47%, and 17%, respectively) and week 56 
(36%, 41%, and 12%, respectively).
ADA induces remissions more frequently than placebo 
in adult patients with CD who cannot tolerate IFX or are 
symptomatic despite receiving IFX therapy.103 In a relevant 
study 21% of patients in the ADA group versus 7% of 
those in the placebo group achieved remission at week 4. 
A 70-point response occurred at week 4 in 52% of patients 
in the ADA group versus 34% of patients in the placebo 
group.   Therefore, ADA is well tolerated and appears to be 
a beneficial option for patients with CD who have lost their 
response to or cannot tolerate IFX, for non-smokers, for 
patients with short duration of CD, and for patients with 
extraintestinal manifestations who have a better clinical 
response.104 Moreover, patients with moderate-to-severe CD 
treated with ADA had lower 1-year risks of hospitalization 
and surgery than placebo patients.105Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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ADA has also excellent results in healing of draining 
fistulas in patients with active CD.106 It was found that the 
mean number of draining fistulas per day was significantly 
decreased in ADA-treated patients compared with placebo-
treated patients. ADA therapy was more effective than 
  placebo for inducing fistula healing and complete fistula 
healing was sustained for up to 2 years by most patients.
Adalimumab in ulcerative colitis
The results on efficacy and safety of ADA for the induc-
tion of remission in anti-TNF naive patients with moder-
ately to severely active UC were recently published.107 In 
this study 18.5% of patients in the ADA 160 mg/80 mg 
group (P = 0.031 versus placebo) and 10.0% in the ADA 
80 mg/40 mg group (P = 0.833 versus placebo) were in 
remission at week 8, compared with 9.2% in the placebo 
group. Serious adverse events occurred in 7.6%, 3.8% and 
4.0% of patients in the placebo, ADA 80 mg/40 mg, and 
ADA 160 mg/80 mg groups, respectively. ADA was safe and 
effective for induction of clinical remission in patients with 
moderate to severely active UC failing treatment with CSs 
and/or immunosuppressants.
The efficacy of ADA in patients with UC who lost the 
response or became intolerant to IFX was also studied in a 
small number of patients.108 In an open-label study, ADA 
induction therapy with 160 mg/80 mg resulted in remission 
at week 4 in four out of ten patients while three other patients 
improved.
In a more recent study on patients with UC who lost 
response to IFX, ADA achieved clinical response at weeks 
4 and 12 in 53% and 60% of patients, respectively, and 
clinical remission in 10% and 27% of patients, respectively. 
After a mean 48-week follow-up, 50% of patients continued 
on ADA. All patients who achieved clinical response at week 
12 were colectomy free in the long term.109
Certolizumab pegol
Certolizumab pegol (CZP) is an antigen-binding fragment 
(Fab’) portion of an IgG antibody attached to a 40-kDa poly-
ethylene glycol moiety to increase the t1/2 of the treatment to 
approximately 2 weeks. The drug has been approved in the 
United States for use in patients with CD not responding to 
conventional treatment, while in Europe it is approved only 
in Switzerland for the treatment of CD (Table 4).
A phase II trial demonstrated the efficacy of a 400 mg 
sc dose of the drug.110 Subsequently, the efficacy of 
CZP was evaluated in two studies (PRECiSE 1 and 2). 
Patients with moderate-to-severe CD (n = 662) were 
  randomly assigned to 400 mg CZP or placebo at weeks 0, 
2, and 4.111 Maintenance therapy was administered every 
4 weeks. Induction of remission as a primary end-point 
was evaluated at weeks 6 and 26. Response rates were 
higher in the CZP group than in the placebo group at 
both time points (35% versus 27% and 23% versus 16%, 
respectively). Patients with elevated CRP levels showed 
a more   pronounced improvement.
In the PRECiSE 2 study the efficacy of maintenance 
therapy in 668 patients with moderate-to-severe CD was 
evaluated.112 Maintenance of response was significantly 
higher in the active treatment group (63% versus 36%).
The PRECiSE 3 study evaluated the long-term results 
of CZP administration.113 The observational period was 
3.5 years. Long-term remission rates were observed in the 
PRECiSE 3 patients receiving CZP and specifically in patients 
with no previous exposure to other TNF inhibitors.
The WELCOME study revealed that location of CD, 
resection, number of resections, and baseline disease activ-
ity have a significant impact on the probability of achieving 
remission after 26 weeks of treatment.114
Evidence for mucosal healing has now been provided for 
CZP.115 Maintenance therapy with CZP resulted in significant 
and clinically meaningful improvements in health-related 
quality of life. Furthermore, a significant proportion of 
patients who received CZP returned to a normal life com-
pared with those who received placebo.116
In a population of CD patients with perianal disease, CZP 
induced a response and remission rates in 54% and 40% 
of patients, respectively. The drug seems to be effective in 
perianal fistulizing CD.117
Another study examined whether fistula closure is main-
tained at week 26 after treatment with CZP. It was found that 
at this time, 36% of patients in the CZP group had 100% 
fistula closure compared with 17% of patients receiving 
placebo (P = 0.038). It seems therefore that continuous treat-
ment with CZP improves the likelihood of sustained perianal 
fistula closure compared with placebo.118
The published controlled trials regarding the use of 
CZP in the treatment of CD share similar limitations with 
other   studies of TNF-α antagonists including high placebo 
response, natural course of disease fluctuation, and the use of 
CDAI to assess outcomes. However, CZP is considered to be 
an effective agent for adult patients with moderate-to-severe 
CD. CZP and ADA, unlike IFX, can be   self-administered. 
With similarity in cost and the lack of head-to-head Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
198
Triantafillidis et al
  comparisons, patient and physician preference may determine 
choice of TNF-α antagonist.119
Side-effects of anti-TNF-α factors
The most significant side-effects are related to opportunistic 
infections, malignancies, as well as injection/infusion reactions 
and appearance of autoimmunity. Contraindications include the 
presence of heart failure and acute infectious diseases. Clinicians 
should be aware that because of the powerful immunosuppres-
sive capacity of biological agents, a rigorous and careful long-
term safety follow-up should be adopted for all patients.120
A meta-analysis of anti-TNF trials evaluated the data of 
21 studies involving 5356 patients (3341 patients in the anti-TNF 
groups and 2015 patients in the control groups).121 There was no 
difference in the frequency of death between the anti-TNF-α and 
control groups. Overall analysis of anti-TNF trials did not show 
any differences between anti-TNF-α and control groups in severe 
infections. Frequency of   malignancies did not differ between 
treated and control groups. An increased number of hepatosplenic 
T-cell lymphoma in young patients highlighted the question of 
malignancies in patients treated with TNF-α inhibitors.
Both the US Food and Drug Administration and the 
  European Crohn’s and Colitis Organization categorize anti-
TNF agents as safe during pregnancy.122 Live-virus vaccines 
are generally contraindicated in patients receiving immu-
nosuppressive regimens due to risks of vaccine-associated 
infection. While patients on immunosuppressives develop 
immune responses after vaccinations, these may be impaired 
relative to their non-immunosuppressed counterparts.123
Before starting treatment with biologic agents it is 
extremely important to assess patients’ prior tuberculosis 
exposure by performing a tuberculin skin test (Mantoux 
test) and a chest X-ray, as the use of these biologic agents 
has been associated with reactivation of a latent tuberculosis. 
New IFN-γ assays may enhance screening efficacy.
It has been proposed that a Mantoux test in patients with 
IBD (especially in patients with CD) seems to be meaningless 
based on the very high incidence of anergy in CD due to the dis-
ease itself, treatment with CSs, and poor nutritional status.124
According to data on patients with active UC, the inci-
dence of anergy to the Mantoux test (16%) did not differ from 
that in normal controls (20%). On the other hand, in patients 
with active CD the incidence of anergy was significantly 
lower compared with normal people (20% vs 52%).125
We suggest that a Mantoux test must be performed both 
in all patients with active IBD, although in patients with CD 
a negative Mantoux test does not exclude the possibility of 
latent tuberculosis.126
Table 4 Certolizumab in Crohn’s disease
Study Number of  
patients
Duration of  
treatment
Comparisons Primary  
end-point
Response to  
treatment
Schreiber118 
PRECiSE 2 
subpopulation
CZP n = 28 
Fistulizing disease
Placebo n = 30
26 weeks CZP vs placebo closure of fistula 36% vs 17% 
(P = 0.038)
Schoepfer117 n = 50 6 weeks CZP 400 mg sc  
at weeks 0, 2, and 4
Response and  
remission rates
Response = 54% 
Remission = 40% 
Effectiveness in  
fistulizing disease
Schreiber112 n = 428 26 weeks Induction therapy,  
400 mg CZP at weeks  
0, 2, and 4. Patients  
with clinical response  
received 400 mg CZP  
or placebo/4 weeks  
through week 24
Maintenance of  
response through  
week 26. Baseline  
CRP . 10 mg/L
Response was maintained through 
week 26 in 62% of CZP vs 34% of 
placebo, P , 0.001) 
Among patients with response 
to induction therapy remission at 
week 26 was seen in 48% of CZP vs 
29% of placebo (P , 0.001).
Sandborn111 n = 662 Patients were stratified  
according to baseline  
CRP. Treatment:  
either 400 mg of CZP or  
placebo at weeks 0, 2,  
and 4 and then every  
4 weeks
Patients with CRP . 10 mg: 
37% in CZP group had response 
at week 6, vs 26% in the placebo 
group (P = 0.04). 
At weeks 6 and 26, the 
corresponding values were 22% and 
12% (P = 0.05). Overall, response 
rates at week 6: 35% in CZP vs 27% 
in placebo (P = 0.02)
Abbreviations: CRP, C-reactive protein; CZP, certolizumab pegol.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
199
Current and emerging drugs for IBD
Prophylaxis regimen will vary from country to country 
depending on resistance prevalence. In patients with a 
positive Mantoux test, isoniazide must be administered 
for 9 months. TNF-α antagonist should be started only 
after 1 month of treatment with isoniazide. Rifampicin 
for 4 months has also been suggested although it does not 
seem as good as an isoniazide regimen. We must bear in 
mind, however, that patients positive on screening who 
are treated with isoniazide and subsequently receive 
biologic agents still have an approximately 19% risk for 
tuberculosis.127
Postsurgical treatment of patients with Crohn’s disease 
with biologic agents
CD commonly recurs after intestinal resection. Administra-
tion of IFX after intestinal resection for CD is effective in 
preventing endoscopic and histologic recurrence. In a small 
trial the rate of endoscopic recurrence at 1 year was signifi-
cantly lower in the IFX group (1 of 11 patients; 9.1%) than the 
placebo group (11 of 13 patients; 84.6%).127 Larger studies 
may be desirable to strengthen the available data.
A thorough understanding of the mechanisms involved 
in the effectiveness of IFX in the postoperative setting could 
substantially improve our therapeutic strategies for overall 
patient management.128
Conclusion
The development of biologic agents and their use in IBD has 
improved patient quality of life considerably by modifying 
disease course and preventing complications and surgery. 
Control of inflammation can be achieved with all three 
available biologic agents, namely IFX, ADA, and CZP. 
These agents are effective in both induction and main-
tenance of remission. For fistula healing, both IFX and 
ADA are effective. Anti-TNF agents appear to be more 
effective in patients who have a shorter disease history and 
who have not yet been treated with any of these agents. 
Patients with CD who were treated with IFX plus AZ or 
IFX monotherapy are more likely to have a CS-free clinical 
remission than those receiving AZ monotherapy. Several 
strategies can minimize the risks associated with biologic 
therapies. Proper strategies include careful examination of 
past history and physical examination and screening for 
latent tuberculosis. During treatment, patients should be 
closely monitored. Education of physicians and patients is 
also important to allow the early detection of any adverse 
effect.
Emerging therapeutic options for 
inflammatory bowel disease
During recent years quite a large number of substances 
have been studied in patients with IBD. Apart from TNF-α 
inhibitors other molecules such as unfractionated or 
  low-molecular-weight heparin, omega-3 polyunsaturated 
fatty acids, microbes, and microbial products have been 
  studied.   Leucocytapheresis, a method developed and applied 
mainly in Japan, also seems to be a promising therapeutic 
strategy.
The emerging therapeutic options for IBD are summa-
rized below.
New and emerging biologic agents
So far, most patients with IBD are treated with rather unspe-
cific medications exerting mainly anti-inflammatory or sup-
pressive effects on the mucosal immune system. Although 
biologic agents directed against TNF-α represent an effec-
tive treatment, 30% of patients with CD will not respond to 
induction therapy, and of those who initially respond, 50% 
will cease to respond within a year. During the last decade a 
better understanding of the underlying pathogenesis of IBD 
along with great advances in biotechnology has enabled the 
introduction of many biologic therapies, other than anti-TNF 
therapies, aiming to act on specific targets.129
We now can target many other proteins or receptors 
including the protein subunit p40 which heterodimerizes 
either with p35 resulting in the pro-inflammatory cytokine 
IL-12 or with p19, thus forming the pro-inflammatory IL-23, 
as well as antibodies that are able to block adhesion molecules 
in the areas of inflammation. Multiple genes that have been 
linked to alterations in immune pathways could also provide 
ways for understanding the pathogenesis of IBD and suggest-
ing future drug targets.130 Many of these drugs have shown 
clinical benefit for induction and maintenance therapy in IBD, 
while others are under evaluation. Experimental data also 
indicate that pro-inflammatory cytokines play a significant 
role in promoting tumor development. The anti-cytokine 
agents could also be efficacious in preventing the onset of 
inflammation associated colorectal cancer.131
Anti-adhesion (anti-integrin) molecules
IBD is driven by the trafficking of lymphocytes from the 
circulation into the gut. Several endothelial adhesion mol-
ecules including E-selectin, ICAM-1, ICAM-2, VCAM-1, 
and mucosal addressin Mad-CAM-1, could enhance inflam-
mation by trafficking leucocytes and recruiting immune Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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cells into the gut. These molecules interact with integrins on 
leukocytes, thus inducing their migration from blood vessels 
into the site of inflammation.
The adhesion molecules involved represent attractive 
targets for the development of new drugs, which should aid 
in reducing existing inflammation and preventing recur-
rence of inflammation, and may lead to long-term control 
of disease.132
Natalizumab
Natalizumab is a humanized IgG4 monoclonal antibody that 
selectively targets the human α4-subunit, thus inhibiting both 
the VCAM-1/α4β1 and MAdCAM-1/α4β7 pathways of leuco-
cyte adhesion and transmigration. It has been approved for the 
treatment of patients with moderate-to-severe CD. This drug 
represents an efficacious therapeutic alternative for patients 
who do not respond to, or have failed, a TNF-α inhibitor.
In the most significant randomized placebo-controlled 
trial on the efficacy of natalizumab in CD, 509 patients 
were allocated to receive either 300 mg natalizumab iv 
or placebo at weeks 0, 4, and 8. Natalizumab induced 
response and remission at week 8 that was sustained 
through week 12. Response and remission rates for natali-
zumab were superior to those for placebo at weeks 4, 8, 
and 12,   demonstrating the early and sustained efficacy of 
the drug as induction therapy in patients with elevated CRP 
and active CD.133 Side-effects did not differ significantly 
between the two groups, although in the open-label exten-
sion of the study, one patient died because of progressive 
multifocal leukoencephalopathy.
MLN-02
MLN-02 is a humanized IgG1 monoclonal antibody against 
α4β7 integrin that selectively inhibits leukocyte adhesion in 
the gastrointestinal mucosa. Also, an Fc receptor recognition 
and binding has been detected, thus eliminating complement 
fixation and cytokine release.
In a recent study, patients with active CD were random-
ized to receive iv MLN-02 2.0 mg/kg, MLN-02 0.5 mg/kg, 
or placebo on days 1 and 29. Clinical response rates at day 
57 were 53%, 49%, and 41% in the MLN-02 2.0 mg/kg, 
MLN-02 0.5 mg/kg, and placebo groups while clinical remis-
sion rates at day 57 were 37%, 30%, and 21%, respectively 
(P = 0.04 for the 2.0 mg/kg versus placebo comparison). At 
day 57, 12% and 34% of patients in the 2.0- and 0.5-mg/kg 
groups had clinically significant human anti-human antibody 
levels. This was suggestive of a dose-dependent beneficial 
effect of the drug on clinical remission.134
In a double-blind, placebo controlled trial, 181 patients 
with active UC received iv 0.5 or 2 mg/kg MLN-02 or 
placebo at day 1 and 29. Both doses of MLN-02 achieved 
better clinical and endoscopic response in patients compared 
with placebo.135
Anti-ICAM-1 therapy
ICAM-1 seems to play a role in cell-mediated inflammation, 
specifically cell trafficking.
Alicaforsen (ISIS 2302) is an antisense to ICAM-1 
(CD54) which was specifically designed to inhibit ICAM-1 
expression. Theoretically, alicaforsen could be useful in the 
treatment of IBD patients.
Systemic treatment in CD patients revealed no significant 
results.
In UC patients, topical application in the form of enemas 
has demonstrated some effect in secondary outcomes, and 
initial studies in pouchitis are promising. The compound is 
well tolerated.136
Anti-IL-6R antibodies
Tocilizumab
Tocilizumab is a humanized anti-IL-6 receptor (IL-6R) 
monoclonal antibody which is produced using genetic 
engineering technology. Tocilizumab recognizes both the 
membrane-bound and the soluble form of IL-6R and spe-
cifically blocks IL-6 actions. As a consequence the drug is 
expected to be able to ameliorate inflammatory processes 
resulting from IL-6 overproduction.
The drug has been approved in the European Union for 
treatment of rheumatoid arthritis. It has also been studied for 
potential use in the treatment of CD.137
Immunostimulators
It has been suggested that some defects in the innate immune 
system may play an important role in the pathogenesis of CD. 
In the last 2 years a number of substances stimulating the innate 
immune system have been tested in patients with CD.
Recombinant human granulocyte-macrophage  
colony-stimulating factor (sargramostim)
Sargramostim is a recombinant human   granulocyte-macrophage 
colony-stimulating factor (GM-CSF) that activates innate 
immunity.
In a randomized trial, 87 steroid-dependent CD patients 
received sargramostim and 42 placebo. Significantly more 
sargramostim-treated patients achieved CS-free   remission 
(18.6% versus 4.9%; P = 0.03) and   improvement in Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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  health-related quality of life. However, patients who received 
sargramostim experienced in a greater degree   musculoskeletal 
pain, injection site reactions, and dyspnea compared with 
  placebo.138 In another study the subcutaneous administra-
tion of sargramostim at a dose of 6 µg/kg/day improved the 
CDAI score although only a minority of patients experienced 
clinical remission or clinical response.139 Finally, 124 patients 
with moderate/severe CD received 6 µg/kg of sargramostim 
sc or placebo daily for 56 days. Although the primary end-
point (reduction of the CDAI of at least 70 points at day 57) 
was not achieved, all secondary end-points were achieved.140 
The drug must be further investigated.
Recombinant human granulocyte-colony  
stimulating factor (filgrastin)
Filgrastin, a recombinant human granulocyte-colony stimu-
lating factor (G-CSF), has also been tested in CD. Twenty 
patients with active CD received daily 300 µγ rhu G-CSF 
sc in a 12-week open-label study. At week 12, 25% of 
patients achieved clinical remission while 55% and 35% 
achieved 70 and 100 point reductions in the CDAI score, 
respectively. There were no significant side-effects except 
mild bone pain.141
Growth factors
Human growth factors are signaling molecules that lead to 
ligand-specific signal transduction. Their downstream effects 
are associated with several cellular functions including epi-
thelial healing in response to injury. Impaired epithelial repair 
represents an important pathophysiological event in IBD.
Specific growth factor deficiencies have been noted 
in patients with IBD. The mode of action of these factors 
seems to be related to reduction of bowel permeability and 
enhancement of mucosal healing.
Several growth factors including growth hormone, 
epidermal growth factor, keratinocyte growth factor, tedug-
lutide, and GM-CSF/G-CSF have emerged as potential tools 
for the modulation of intestinal inflammation and repair. 
Despite promising results of initial studies, the evidence 
to justify treatment of patients is inadequate. Specifically, 
keratinocyte growth factor-2 and epidermal growth factor 
did not show efficacy in phase II trials concerning patients 
with either CD or UC.142
T-cell directed therapies
In patients with IBD, T-cell-mediated immune responses 
directed against normal components of the gut flora play 
a significant role in amplifying and sustaining the mucosal 
inflammation by producing huge amounts of cytokines. 
Strategies aimed at interfering with T-cell accumulation 
and/or function in the gut have been employed with clinical 
success in patients with IBD.143
Therapeutic targets include modulators of CD80 or 
CD86-CD28 co-stimulatory signal (abatacept), CD2 recep-
tors on T-cells (alefacept), CD11a, subunit of leukocyte 
function-associated antigen 1 (efalizumab), vitronectin 
receptor, and CD20 antigen on pre-B, immature, and mature 
B cells (rituximab).144
Inhibitors of Th1 polarization
It has been shown that in patients with CD the production of 
IL-12 and IL-18 results in Th1 polarized immune response 
and increased secretion of pro-inflammatory cytokines. It is 
logical therefore to test the efficacy of agents aiming to block 
the production of IL-12 and IFN-γ in patients with CD.
Anti-INF-γ antibodies (fontolizumab)
Fontolizumab is a humanized anti-IFN-γ antibody that has 
been tested recently in patients with CD. The administration 
of this antibody is based on the knowledge that elevated 
gut mucosal levels of INF-γ are associated with disease 
symptoms.
A total of 201 patients with active CD was randomized 
to receive an initial iv dose of 1.0 or 4.0 mg/kg fontoli-
zumab or placebo, followed by up to three sc doses of 0.1 or 
1.0 mg/kg fontolizumab or placebo every 4 weeks. On day 
29 response rates were similar in all treatment groups (31% 
to 38%). Subsequently a greater proportion of patients in 
the 1.0 mg/kg iv/1.0 mg/kg sc fontolizumab group achieved 
clinical response and greater improvement in the CDAI score 
compared with patients who received placebo. All fontoli-
zumab groups had significant improvement in CRP levels. 
The frequency of adverse events was similar in all groups.145 
Although a strong clinical response to fontolizumab was 
not observed, significant decrease in CRP levels suggest a 
biological effect.
Anti IL-12 antibodies (ustekinumab)
Ustekinumab is a monoclonal antibody against the p40 
subunit of IL-12/23, 2 important cytokines implicated in 
CD pathophysiology.
In a double-blind, cross-over trial 104 patients with 
moderate-to-severe CD were given sc placebo at weeks 0 
to 3, then ustekinumab at weeks 8 to 11; sc ustekinumab 
at weeks 0 to 3, then placebo at weeks 8–11; iv placebo 
at week 0, then ustekinumab at week 8; or iv ustekinumab Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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at week 0, then placebo at week 8. Clinical response rates 
for the   combined groups given ustekinumab and placebo 
were 53% and 30% (P = 0.02), respectively at weeks 4 and 
6, and 49% and 40% (P = 0.34), respectively, at week 8. In 
a subgroup of 49 patients who were previously given IFX, 
clinical response to ustekinumab was significantly greater 
than the group given placebo through week 8. Furthermore, 
in an open-label trial on the effects of 4 weekly sc injections 
or one iv infusion of ustekinumab in 27 patients who were 
non-responders to IFX, the clinical responses at week 8 to sc 
and iv ustekinumab were 43% and 54%, respectively.146 In a 
subsequent analysis of the alterations of levels of serum CRP 
the authors stressed that the potential benefit of ustekinumab 
in CD was further supported by serum CRP reduction. It 
seems that increased systemic inflammation as manifested 
by higher baseline CRP values leads to larger treatment 
effects with ustekinumab, especially in patients previously 
treated with IFX.147
Apilimod
Apilimod mesylate (formerly STA-5326) is an orally admin-
istered IL-12 and IL-23 inhibitor.
A phase II study evaluated the efficacy of the drug in treat-
ing 220 adult patients with CD. Patients received placebo or 
apilimod mesylate 50 or 100 mg daily. A clinical response was 
experienced by 24.7% in the 50-mg daily group and by 25.7% in 
the 100-mg group, compared with 28.8% in the placebo group 
on day 29 (no significant differences). Apilimod did not dem-
onstrate efficacy over placebo in patients with active CD.148
Inhibitors of T-cell proliferation
Selective blockade of lymphocyte-vascular endothelium 
interactions in the gastrointestinal tract seems to be a promis-
ing therapeutic strategy for IBD. A number of monoclonal 
antibodies have been developed and tested in patients with 
UC during recent years.
Visilizumab
Visilizumab is a humanized IgG2 monoclonal anti-CD3 
antibody. In an open-label phase I study performed on 
patients with severe UC, 32 subjects who had not previously 
responded to a 5-day regime with iv CSs received visilizumab 
at a dose of 10 or 15 µg/kg, on two consecutive days. On day 
30, 84% of patients demonstrated a clinical response, 41% 
achieved clinical remission, and 44% achieved endoscopic 
remission; 45% of patients did not require salvage therapies 
or colectomy during the first year postdose. Mild to moderate 
symptoms of cytokine release occurred in 100% and 83% of 
patients in the 15- and 10-µg/kg dose groups, respectively. 
All patients exhibited a decrease in circulating CD4(+) T-cell, 
which returned to baseline values by day 30 in 26 of 30 
evaluable patients (86%). There were no serious infections. 
Visilizumab had an acceptable safety profile at the 10-µg/kg 
dose level and may be clinically beneficial in patients with 
severe CS-refractory UC.149
In another study 104 patients were treated with visili-
zumab. The drug induced both symptomatic response and 
clinical response. Results with 5 µg/kg/day were similar 
to those observed with higher doses. However, all patients 
experienced adverse events.150
Basiliximab
Basiliximab is a chimeric IgG1 monoclonal antibody that 
targets CD25. This action is not associated with the release 
of cytokines because basiliximab has no cytoplasmic tail.
In an open-label, uncontrolled trial 20 patients with severe 
and moderate steroid-resistant UC were given a single dose 
of 40 mg basiliximab plus standard steroid therapy. Within 
8 weeks, 10 of 20 (50%) patients achieved clinical remis-
sion. At 24 weeks, 13 of 20 (65%) patients were in clinical 
remission. Five patients required colectomy. Treatment was 
well tolerated.151
Basiliximab appears to promote prolonged remission after 
a single treatment, and shows particular promise in moderate 
steroid-resistant UC.
Daclizumab
Daclizumab is a humanized IgG1 monoclonal antibody tar-
geting CD25. In a double blind, placebo-controlled trial, 159 
patients with active UC were randomized to receive induction 
therapy with daclizumab 1 mg/kg iv at weeks 0 and 4, or 
2 mg/kg iv at weeks 0, 2, 4, and 6, or placebo. Two percent 
of patients receiving daclizumab 1 mg/kg (P = 0.11 versus 
placebo) and 7% of patients receiving 2 mg/kg (P = 0.73) 
were in remission at week 8, compared with 10% of those 
who received placebo. Response occurred at week 8 in 25% 
of patients receiving daclizumab 1 mg/kg (P = 0.04) and in 
33% of patients receiving 2 mg/kg (P = 0.30) versus 44% of 
those receiving placebo. Patients with moderate UC who are 
treated with daclizumab are not more likely to be in remission 
or response at 8 weeks than patients treated with placebo.152
Anti-inflammatory cytokines
Recombinant human IL-10
In a recent meta-analysis aim to assess the efficacy and toler-
ability of IL-10 for induction of remission in patients with Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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active CD, no significant differences were found between the 
drug and placebo in complete remission or clinical remission. 
Patients treated with IL-10 were more likely to withdraw 
from the studies due to adverse events. Therefore, IL-10 
does not appear to provide any benefit for the treatment of 
active CD.153
Immunomodulators
IFN-β1a has been shown to downregulate the expression of 
IL-12, a cytokine that is thought to be involved in mucosal 
degeneration in CD.
In a multicenter, double-blind, placebo-controlled, 
phase II, dose-finding study, patients with steroid-induced 
clinical remissions of CD were randomized 1:1:1:1 to sc 
  IFN-β1a: 66 µg three times weekly, 44 µg three times 
weekly, 44 µg twice weekly, or placebo three times weekly 
with steroid tapering. The study was terminated after a 
planned interim analysis at 26 weeks because there was no 
difference in efficacy between patients with CD receiving 
IFN-β1a or placebo.154
Conclusion
During the past decade a better understanding of the underly-
ing pathogenesis of IBD along with great advances in bio-
technology has resulted in the introduction of many biologic 
therapies, other than anti-TNF-α. We now can target many 
other proteins or receptors including the protein subunit p40, 
as well as antibodies that are able to block adhesion molecules 
in the areas of inflammation.
Among the new biologic agents, natalizumab produced 
quite satisfactory results in patients with CD and is currently 
in regular use in the United States. However, attention must be 
given to the possible side-effects of the drug. A good sugges-
tion is to use natalizumab as an alternative therapeutic option 
after failure or intolerance of other anti-TNF-α agents.
Results from trials on the use of antibodies against IL-12 
and IL-6R in patients with CD produced relatively satisfac-
tory results, although studies including large numbers of 
patients are needed. In patients with CS-refractory UC, 
basiliximab could be an effective agent.
We must stress the fact that so far no studies have com-
pared head-to-head anti-TNF antibodies with other biological 
agents belonging to other classes such as natalizumab.
Despite promising results of the initial studies on the 
use of growth factors, the evidence to justify treatment of 
patients with CD is inadequate. Because the administration of 
anti-inflammatory cytokines or immunomodulators produced 
negative results their use at present is not justified.
Ustekinumab, the monoclonal antibody against the 
p40 subunit of IL-12/23, seems to be promising in patients 
with active CD, especially in those with high baseline CRP 
values.
Because the data on the efficacy and short- and long-term 
safety of these new biologic agents are limited, their use in 
IBD patients remains to be justified.
Microbes and microbial products
Helminths
In Western countries modern hygienic practices prevent 
exposure to parasitic worms. Epidemiologic studies sug-
gest that people harboring infection from helminths are 
affected by immune-mediated disease to a lesser degree. 
Consequently, people living in less developed countries are 
probably protected from IBD development. This epidemio-
logical assumption is further supported by experimental data 
showing that mice colonized with helminths are protected 
from the development of experimental colitis.155 The ‘IBD 
hygiene hypothesis’ states that raising children in extremely 
hygienic environments impairs immune development, which 
predisposes them to immunological diseases such as IBD 
later in life.156 Helminths stimulate immune regulatory cir-
cuitry by interacting with host innate and adoptive immunity, 
thus reducing aberrant inflammation.
It seems therefore that exposure to helminths may help 
prevent or even ameliorate IBD. The most important studies 
on the safety and possible efficacy of the intestinal helminth 
Trichuris suis in the treatment of patients with active CD are 
discussed below.
Efficacy of helminths in Crohn’s disease
Twenty-nine patients with active CD ingested 2500 live 
T. suis ova every 3 weeks for 24 weeks. At week 24, 79.3% 
responded and 72.4% remitted. Analysis at week 12 yielded 
similar results.157 There were no adverse events. Helminth 
therapy may offer a unique, safe, and efficacious alternative 
for CD management.
Efficacy of helminths in ulcerative colitis
In animal models, helminths prevent or improve colitis by 
inducing regulatory T cells and modulatory cytokines.
In a randomized, double blind, placebo-controlled trial 
aiming to determine the efficacy and safety of the helminth 
T. suis in UC, Summers et al assigned 54 patients with 
active UC, to receive 2500 T. suis ova or placebo orally at 
2-week intervals for 12 weeks. After 12 weeks, improvement 
occurred in 43.3% of patients with ova treatment compared Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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with 16.7% given placebo (P = 0.04). Treatment induced 
no side-effects.158
Cholera toxin B subunit
Cholera toxin B subunit has been shown to ameliorate experi-
mentally induced colitis in mice.
In a recent study aim to evaluate the safety and efficacy 
of recombinant cholera toxin B subunit in CD patients, an 
oral solution of 5 mg recombinant cholera toxin B sub-
unit was administered to 15 patients with CD three times 
per week for 2 weeks. A significant decrease in CDAI score 
was observed. Response rates were 42% in the per-protocol 
analysis; 40% were in remission at 4 weeks and 30% at 
8 weeks post-  treatment.159 No significant side-effects were 
noted.   Treatment with recombinant cholera toxin B subunit 
seems to be safe, leading to a 40% treatment response.
Conclusion
The results of these studies suggest that microbes and 
microbial products (especially ova therapy) could be a 
safe and effective therapy in patients with both active CD 
and active UC. However, we suggest that further studies 
including a large number of patients with different types of 
IBD are needed before considering helminth treatment as an 
  alternative therapy for patients with IBD.
Omega-3 free fatty acids
Because of their anti-inflammatory action, omega-3 poly-
unsaturated fatty acids (PUFA) may be beneficial in IBD. 
A large body of evidence supports a protective effect of 
omega-3 PUFA in experimental animals and ex vivo models 
of CD and UC. Although fish oil supplementation in patients 
with IBD results in omega-3 PUFA incorporation into gut 
mucosal tissue and modification of inflammatory mediator 
profiles, the evidence of clinical benefits of omega-3 PUFA 
is weak.160
A study aim to determine whether the oral administration 
of omega-3 free fatty acids is more effective than placebo for 
prevention of relapse of CD showed that 4 g/day of omega-3 
free fatty acids for up to 58 weeks was not more effective in 
preventing relapse of CD than placebo.161
Leukocytapheresis
In patients with active IBD a large number of activated 
myeloid leucocytes infiltrate the colonic mucosa. Myeloid 
leucocytes produce large amounts of TNF-α. It is possible, 
therefore, that selective granulocyte/monocyte adsorption 
could promote remission in active UC. The mode of action 
of granulocyte/monocyte adsorption appears to be more 
than adsorption of excess neutrophils and TNF-producing 
  monocytes. Adsorbed granulocyte/monocytes release IL-1 
receptor antagonist, hepatocyte growth factor, and soluble 
TNF receptors, which have anti-inflammatory properties.162
It is generally accepted that leukocytapheresis treatment 
of patients refractory to conventional UC therapy could 
produce very satisfactory results.163
More intensive leukocytapheresis seems to be more 
efficacious than weekly treatment. It can significantly reduce 
patient morbidity time without increasing the incidence of 
side-effects.164
Unfractioned and low-molecular-weight 
heparin
According to a recent meta-analysis on the use of unfraction-
ated heparin and low-molecular-weight heparins (LMWH) in 
patients with active UC, sc LMWH showed no benefit over 
placebo. However, high doses of LMWH administered via 
an extended colon-release tablet demonstrated benefit over 
placebo for clinical remission and clinical and endoscopic 
improvement. There is evidence to suggest that LMWH may 
be effective for the treatment of active UC, a benefit that needs 
to be confirmed by randomized controlled   studies. There is 
no evidence, however, to support the use of unfractionated 
heparin for the treatment of active UC. When deciding to 
administer LMWH in patients with active UC the benefit must 
be balanced against an increased risk of rectal bleeding.165
Other substances
Anti-oxidants
Oxidative stress plays a significant role in the pathogenesis 
of IBD. In a preliminary study it was reported that rectal 
d-alpha tocopherol enema (8000 U/day) may represent a 
novel therapy for mild and moderately active UC, probably 
owing to the anti-inflammatory and anti-oxidative properties 
of vitamin E.166
Statins
Experimental and clinical data have suggested that statins can 
downregulate both acute and chronic inflammatory processes. 
In a study including a small number of patients, atorvastatin 
therapy reduced inflammation in patients with CD, thus 
encouraging further investigation in IBD patients.167
Rosiglitazone
Thiazolidinedione ligands for PPAR-γ receptors have been 
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Dovepress 
Dovepress
205
Current and emerging drugs for IBD
In a randomized, double-blind, placebo-controlled 
  clinical trial the efficacy of rosiglitazone 4 mg orally twice 
daily versus placebo twice daily for 12 weeks was studied 
in 105 patients with mild-to-moderate UC. Rosiglitazone 
was shown to be efficacious.168 In another study combined 
treatment with rosiglitazone and mesalazine achieved better 
results than mesalazine alone.
Rosiglitazone can alleviate colonic inflammation, which 
we hope will become a novel agent for UC treatment.169
Drugs used in the treatment of pouchitis
Pouchitis is the major long-term complication after 
ileal-pouch-anal anastomosis for UC. More than 15% of 
operated patients can develop chronic pouchitis, either 
treatment-responsive or treatment-refractory. During recent 
years the treatment of refractory pouchitis has progressed 
significantly.
In a Cochrane systematic review on the efficacy of 
medical therapies for pouchitis it was found that cipro-
floxacin was more effective in inducing remission than 
metronidazole. Lactobacillus GG were more effective 
than placebo, while budesonide enemas and metronida-
zole were similarly effective in inducing remission of 
the active disease. Other substances were also tried in 
patients with pouchitis (including glutamine and butyrate 
suppositories) but unfortunately produced no statistically 
significant results.
Bismuth carbomer foam enemas did not show efficacy, 
while VSL#3 was more effective than placebo in maintaining 
remission of chronic pouchitis. For the prevention of   pouchitis, 
allopurinol and inulin also seem to be of benefit.170
Budesonide
In an open-label study 20 patients with active pouchitis 
not responding after 1 month of antibiotic treatment were 
treated with budesonide controlled ileal release 9 mg/day 
for 8 weeks; 75% achieved remission. Budesonide seems 
to be an important alternative treatment in this kind of 
patient.171
Rifaximin
In a placebo-controlled pilot study aiming to evaluate the 
efficacy and safety of rifaximin 400 mg or placebo three times 
daily for 4 weeks in patients with active pouchitis, clinical 
remission occurred more frequently in patients treated with 
rifaximin but the difference was not significant in this pilot 
study. Further studies are required in order to determine if 
rifaximin is effective in active pouchitis.172
Conclusion
During the last decade we have seen the development of a 
large number of biological agents against TNF-α, as well 
as many biochemical substances and molecules specifically 
for the medical treatment of patients with inflammatory 
bowel disease. This revolution was a consequence of sig-
nificant advances in biotechnology along with an increased 
  knowledge of the underlying pathophysiologic mechanisms 
of the disease. Among others, natalizumab has shown quite 
good results in CD patients while basiliximab has shown effi-
cacy in steroid-refractory UC. Leukocytapheresis has shown 
satisfactory results in steroid-refractory patients with UC. 
Unfractionated heparin and LMWH have been studied in 
patients with active UC with encouraging results. Microbes 
and microbial products including eggs of helminths seem to 
reduce disease activity in patients with UC or CD.
Helminths could act as adjuvants for induction of T regu-
latory cells which inhibit the maturation of CD4 T cells to 
Th1 and Th2 effector cells, and reduce the occurrence of Th1-
mediated diseases (such as CD) and Th2-mediated diseases 
(such as UC). Chronic helminth infestation provokes a state 
of chronic immune activation with anergy. Administration of 
ova of T. suis has given encouraging results in the treatment 
of CD and UC with a good safety record, but long-term tri-
als are needed because of the potentially harmful effects of 
helminths on immunity.
Omega-3 fatty acids, antioxidants, statins and many other 
molecules are under investigation.
However, as stressed earlier, the true value of these 
new agents must not be overestimated, as their therapeutic 
success is limited and the costs per induced remission are 
quite high.
It is hoped that this enormous effort to discover new ways 
of treating IBD will make us more optimistic for the future 
of our patients suffering from this enigmatic disease.
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